126 related articles for article (PubMed ID: 38281870)
1. Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study.
Hupé M; Streichenberger A; Wils P; Arab N; Serrero M; Amiot A; Bozon A; Vuitton L; Fumery M; Altwegg R; Nachury M; Hébuterne X; Yzet C; Coban D; Dodel M; Bazoge M; Pereira B; Buisson A
Dig Liver Dis; 2024 Jan; ():. PubMed ID: 38281870
[TBL] [Abstract][Full Text] [Related]
2. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Calafat M; Torres P; Tosca-Cuquerella J; Sánchez-Aldehuelo R; Rivero M; Iborra M; González-Vivo M; Vera I; de Castro L; Bujanda L; Barreiro-de Acosta M; González-Muñoza C; Calvet X; Benítez JM; Llorente-Barrio M; Surís G; Cañete F; Arias-García L; Monfort D; Castaño-García A; Garcia-Alonso FJ; Huguet JM; Marín-Jímenez I; Lorente R; Martín-Cardona A; Ferrer JÁ; Camo P; Gisbert JP; Pajares R; Gomollón F; Castro-Poceiro J; Morales-Alvarado J; Llaó J; Rodríguez A; Rodríguez C; Pérez-Galindo P; Navarro M; Jiménez-García N; Carrillo-Palau M; Blázquez-Gómez I; Sesé E; Almela P; Ramírez de la Piscina P; Taxonera C; Rodríguez-Lago I; Cabrinety L; Vela M; Mínguez M; Mesonero F; García MJ; Aguas M; Márquez L; Silva Porto M; Pineda JR; García-Etxebarría K; Bertoletti F; Brunet E; Mañosa M; Domènech E
Therap Adv Gastroenterol; 2024; 17():17562848231221713. PubMed ID: 38187926
[TBL] [Abstract][Full Text] [Related]
3. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).
Sassaki LY; Magro DO; Saad-Hossne R; Baima JP; Flores C; Correia LM; Celani LMS; De Abreu Ferrari ML; Zacharias P; Feitosa MR; Dos Santos CHM; De Freitas Lins Neto MA; Quaresma AB; De Lima Junior SF; De Vasconcelos GBS; Cassol OS; Dos Santos Pinto A; Kurachi G; Goncalves Filho FA; Gasparini RG; Furlan TK; Catapani WR; Coy CSR; De Souza Menegassi V; Colombo MM; Fróes RSB; Teixeira FV; Moraes AC; Santana GO; Parente JML; Vilela EG; Queiroz NSF; Kotze PG;
BMC Gastroenterol; 2022 May; 22(1):268. PubMed ID: 35644668
[TBL] [Abstract][Full Text] [Related]
5. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis.
Frin AC; Filippi J; Boschetti G; Flourie B; Drai J; Ferrari P; Hebuterne X; Nancey S
Dig Liver Dis; 2017 Jan; 49(1):11-16. PubMed ID: 27693318
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
Hupé M; Rivière P; Nancey S; Roblin X; Altwegg R; Filippi J; Fumery M; Bouguen G; Peyrin-Biroulet L; Bourreille A; Caillo L; Simon M; Goutorbe F; Laharie D
Aliment Pharmacol Ther; 2020 May; 51(9):852-860. PubMed ID: 32201971
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
8. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
Mahmoud R; Savelkoul EHJ; Mares W; Goetgebuer R; Witteman BJM; de Koning DB; van Tuyl SAC; Minderhoud I; Lutgens MWMD; Akol-Simsek D; van Schaik FDM; Fidder HH; Jansen JM; van Boeckel PGA; Mahmmod N; Horjus-Talabur Horje CS; Römkens TEH; Colombel JF; Hoentjen F; Jharap B; Oldenburg B;
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):750-760.e4. PubMed ID: 36055567
[TBL] [Abstract][Full Text] [Related]
9. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
Buisson A; Nachury M; Guilmoteau T; Altwegg R; Treton X; Fumery M; Serrero M; Leclerc E; Caillo L; Pereira B; Amiot A; Bouguen G
Aliment Pharmacol Ther; 2023 Mar; 57(6):676-688. PubMed ID: 36401585
[TBL] [Abstract][Full Text] [Related]
10. Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy.
Messadeg L; Hordonneau C; Bouguen G; Goutorbe F; Reimund JM; Goutte M; Boucher AL; Scanzi J; Reymond M; Allimant C; Dapoigny M; Pereira B; Bommelaer G; Buisson A
J Crohns Colitis; 2020 Nov; 14(11):1524-1534. PubMed ID: 32533769
[TBL] [Abstract][Full Text] [Related]
11. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
Dhaliwal J; McKay HE; Deslandres C; Debruyn J; Wine E; Wu A; Huynh H; Carman N; Crowley E; Church PC; Walters TD; Ricciuto A; Griffiths AM;
Aliment Pharmacol Ther; 2021 Jun; 53(12):1300-1308. PubMed ID: 33909911
[TBL] [Abstract][Full Text] [Related]
12. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure.
Bae JH; Park JB; Baek JE; Hong SW; Park SH; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Hwang SW
Gut Liver; 2024 Jun; ():. PubMed ID: 38835325
[TBL] [Abstract][Full Text] [Related]
14. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
[TBL] [Abstract][Full Text] [Related]
15. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
[TBL] [Abstract][Full Text] [Related]
16. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.
Pouillon L; Baumann C; Rousseau H; Choukour M; Andrianjafy C; Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2019 Apr; 25(5):945-954. PubMed ID: 30329067
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.
Taxonera C; Iglesias E; Muñoz F; Calvo M; Barreiro-de Acosta M; Busquets D; Calvet X; Rodríguez A; Pajares R; Gisbert JP; López-Serrano P; Pérez-Calle JL; Ponferrada Á; De la Coba C; Bermejo F; Chaparro M; Olivares D; Alba C; Fernández-Blanco I
Dig Dis Sci; 2017 Feb; 62(2):481-490. PubMed ID: 27995400
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab.
Miller C; Kwok H; Harrow P; Vega R; Seward E; Mehta S; Rahman F; McCartney S; Parisi I; Lim SH; Sharma E; Samaan MA; Bancil A; Kok KB; Shalabi A; Johnston EL; Katarey D; Taherzadeh N; Murray C; Sharip MT; Carter MJ; Radhakrishnan ST; Peake S; Khakoo I; Wahed M; Povlsen S; Patel M; DuBois P; Finkel J; Onnie C; Bloom S
Frontline Gastroenterol; 2022; 13(5):392-401. PubMed ID: 36051959
[TBL] [Abstract][Full Text] [Related]
19. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
[TBL] [Abstract][Full Text] [Related]
20. Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab.
Saigusa K; Matsuoka K; Sugimoto S; Arai M; Kiyohara H; Takeshita K; Mizuno S; Mori K; Nanki K; Takeshita T; Nakazato Y; Yajima T; Naganuma M; Hisamatsu T; Ogata H; Iwao Y; Kanai T
Dig Endosc; 2016 Sep; 28(6):665-70. PubMed ID: 26997640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
